Sarcopenia definition, diagnosis and treatment: consensus is growing

Avan Aihie Sayer, Alfonso Cruz-Jentoft, Avan Aihie Sayer, Alfonso Cruz-Jentoft

Abstract

Sarcopenia is a skeletal muscle disorder that commonly occurs with advancing age as well as with a number of long-term conditions. Recognition in clinical practice is relatively recent but important because of the association between sarcopenia and a range of adverse effects on health including impaired mobility, increased morbidity and mortality. Originally characterised as loss of muscle mass, the definition has evolved to focus on loss of skeletal muscle function, particularly strength, through a number of international definitions such as that of the European Working Group on Sarcopenia in Older People most recently revised in 2019. Progress in the decades ahead is likely to be seen with regard to use of routine health data, prescription of resistance exercise, translation of biology and epidemiology into first in man studies for new treatments, and focus on sarcopenia in low and middle-income countries. Immediate next steps include the newly formed Global Leadership Initiative on Sarcopenia to develop international consensus on definition and diagnosis.

Keywords: muscle function; muscle strength; older people; sarcopenia; skeletal muscle mass.

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Geriatrics Society.

Figures

Figure 1
Figure 1
Low muscle mass in the definitions of malnutrition, sarcopenia and cachexia: conceptual crossroads.

References

    1. Rosenberg IH. Summary comments. Am J Clin Nutr 1989; 50: 1231–3.
    1. Clark BC, Manini TM. Sarcopenia =/= dynapenia. J Gerontol A Biol Sci Med Sci 2008; 63: 829–34.
    1. Sanchez-Rodriguez D, Marco E, Cruz-Jentoft AJ. Defining sarcopenia: some caveats and challenges. Curr Opin Clin Nutr Metab Care 2020; 23: 127–32.
    1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet 2019; 393: 2636–46.
    1. Anker SD, Morley JE, Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle 2016; 7: 512–4.
    1. Cruz-Jentoft AJ, Bahat G, Bauer Jet al. . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16–31.
    1. Chen L-K, Woo J, Assantachai Pet al. . Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020; 21: 300–307.e2.
    1. Dent E, Morley JE, Cruz-Jentoft AJet al. . International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management. J Nutr Health Aging 2018; 22: 1148–61.
    1. Bauer J, Morley JE, Schols AMWJet al. . Sarcopenia: a time for action. an SCWD position paper. J Cachexia Sarcopenia Muscle 2019; 10: 956–61.
    1. Miller J, Wells L, Nwulu U, Currow D, Johnson MJ, Skipworth RJE. Validated screening tools for the assessment of cachexia, sarcopenia, and malnutrition: a systematic review. Am J Clin Nutr 2018; 108: 1196–208.
    1. Zanker J, Scott D, Reijnierse EMet al. . Establishing an operational definition of sarcopenia in Australia and New Zealand: Delphi method based consensus statement. J Nutr Health Aging 2019; 23: 105–10.
    1. Bhasin S, Travison TG, Manini TMet al. . Sarcopenia definition: the position statements of the sarcopenia definition and outcomes consortium. J Am Geriatr Soc 2020; 68: 1410–8.
    1. Offord NJ, Clegg A, Turner G, Dodds RM, Sayer AA, Witham MD. Current practice in the diagnosis and management of sarcopenia and frailty – results from a UK-wide survey. J Frailty Sarcopenia Falls 2019; 4: 71–7.
    1. Yeung SSY, Reijnierse EM, Trappenburg MC, Meskers CGM, Maier AB. Current knowledge and practice of Australian and New Zealand health-care professionals in sarcopenia diagnosis and treatment: time to move forward! Australas J Ageing 2020; 39: e185–93.
    1. Reijnierse EM, Schueren MAE, Trappenburg MC, Doves M, Meskers CGM, Maier AB. Lack of knowledge and availability of diagnostic equipment could hinder the diagnosis of sarcopenia and its management. PLoS One 2017; 12: e0185837. 10.1371/journal.pone.0185837.
    1. Wang H, Huang WY, Zhao Y. Efficacy of exercise on muscle function and physical performance in older adults with sarcopenia: An updated systematic review and meta-analysis. Int J Environ Res Public Health 2022; 19: 8212. 10.3390/ijerph19138212.
    1. Negm AM, Lee J, Hamidian R, Jones CA, Khadaroo RG. Management of sarcopenia: a network meta-analysis of randomized controlled trials. J Am Med Dir Assoc 2022; 23: 707–14.
    1. Bernabei R, Landi F, Calvani Ret al. . Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project). BMJ 2022; 377: e068788. 10.1136/bmj-2021-068788.
    1. Bagherniya M, Mahdavi A, Shokri-Mashhadi Net al. . The beneficial therapeutic effects of plant-derived natural products for the treatment of sarcopenia. J Cachexia Sarcopenia Muscle 2022. 10.1002/jcsm.13057.
    1. Evans WJ, Morley JE, Argilés Jet al. . Cachexia: a new definition. Clin Nutr 2008; 27: 793–9.
    1. Cederholm T, Jensen GL, Correia MITDet al. . GLIM criteria for the diagnosis of malnutrition – a consensus report from the global clinical nutrition community. Clin Nutr 2019; 38: 1–9. 10.1016/j.clnu.2018.08.002.
    1. Barazzoni R, Jensen GL, Correia MITDet al. . Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition (GLIM) diagnosis of malnutrition. Clin Nutr 2022; 41: 1425–33.
    1. Moorthi RN, Liu Z, El-Azab SAet al. . Sarcopenia, frailty and cachexia patients detected in a multisystem electronic health record database. BMC Musculoskelet Disord 2020; 21: 508. 10.1186/s12891-020-03522-9.
    1. Dodds RM, Granic A, Robinson SM, Sayer AA. Sarcopenia, long-term conditions, and multimorbidity: findings from UK Biobank participants. J Cachexia Sarcopenia Muscle 2020; 11: 62–8.
    1. Hurst C, Robinson SM, Witham MDet al. . Resistance exercise as a treatment for sarcopenia: prescription and delivery. Age Ageing 2022; 51: afac003.
    1. Kwak JY, Kwon K-S. Pharmacological interventions for treatment of sarcopenia: current status of drug development for sarcopenia. Ann Geriatr Med Res 2019; 23: 98–104.
    1. Feike Y, Zhijie L, Wei C. Advances in research on pharmacotherapy of sarcopenia. Aging Med (Milton) 2021; 4: 221–33.
    1. Rooks D, Swan T, Goswami Bet al. . Bimagrumab vs optimized standard of care for treatment of sarcopenia in community-dwelling older adults: a randomized clinical trial. JAMA Netw Open 2020; 3: e2020836. 10.1001/jamanetworkopen.2020.20836.
    1. Martyn JAJ, Kaneki M. Muscle atrophy and the sestrins. N Engl J Med 2020; 383: 1279–82.
    1. Witham M, Cooper R, Bowden Davies Ket al. . Ageing research translation: a new era for UK Geroscience. Nat Aging 2022; In press.
    1. Migliavacca E, Tay SKH, Patel HPet al. . Mitochondrial oxidative capacity and NAD+ biosynthesis are reduced in human sarcopenia across ethnicities. Nat Commun 2019; 10: 5808. 10.1038/s41467-019-13694-1.
    1. Dodds RM, Syddall HE, Cooper R, Kuh D, Cooper C, Sayer AA. Global variation in grip strength: a systematic review and meta-analysis of normative data. Age Ageing 2016; 45: 209–16.
    1. Essomba MJN, Atsa D, Noah DZet al. . Geriatric syndromes in an urban elderly population in Cameroon: a focus on disability, sarcopenia and cognitive impairment. Pan Afr Med J 2020; 37: 229. 10.11604/pamj.2020.37.229.26634.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe